QLESP Block for Pain Control in Robotic Partial Nephrectomy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHuazhong University of Science and Technology
About this trial
The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are:
1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery? 2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites.
Participants will:
1. Be randomly assigned to receive either QLESP or local wound injection before surgery. 2. Have a patient-controlled pain pump for 48 hours after surgery. 3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery. 4. Be followed until hospital discharge.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 to 75 years
Scheduled for elective robot-assisted partial nephrectomy (RAPN)
American Society of Anesthesiologists (ASA) physical status I to III
Body mass index (BMI) 18 to 35 kg/m²
Disqualifiers
Language, communication, or comprehension barriers
Infection at the intended puncture site
Coagulopathy or bleeding diathesis
Known allergy or contraindication to local anesthetics or opioids
Trial design
Design model
Parallel
Treatments tested in this trial
ropivacaine (local infiltration)
DrugUltrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL injected between the erector spinae muscle and the transverse process at L2 level, followed by 15 mL injected between the quadratus lumborum and psoas major muscles) after induction of general anesthesia.
ropivacaine
DrugLocal wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.
Treatment groups
120 Participants
are divided into 2 treatment groupsGroup A: QLESP GroupExperimental treatment 1 intervention
Group B: Control GroupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Cumulative Opioid Consumption at 48 Hours Postoperatively
Cumulative opioid consumption measured at 48 hours after surgery
Time frame
From the end of surgery to 48 hours postoperatively.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov